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  The successes in the treatment of childhood acute lympho-
blastic leukemia (ALL) are well known, with a cure rate 
of more than 80% of patients treated. However, for the 
minority of patients who fail to achieve long-term remission, 
treatment options are limited with overall poor prognosis. 
Much the same can be said for Burkitt lymphoma today, 
once considered in the same disease category as precursor 
B ALL and erroneously treated in a similar manner.
The major characteristics of Burkitt lymphoma are well 
established; morphologically, Burkitt lymphoma consists of 
a homogenous population of medium-sized cells with a high 
mitotic rate [1]. Immunophenotype spectrum includes ex-
pression of surface IgM, CD19, CD20, CD22, CD10, CD79a, 
and negative results for TdT [2]. Above all, important corrob-
orating evidence for the diagnosis of Burkitt lymphoma 
includes translocations involving the MYC gene at locus 
8q24. These MYC translocations consist of t(8;14)(q24;q32), 
by far the most common, and t(8;22)(q24;q11) and t(2;8) 
(p12;p24) to a much lesser extent, all of which result in 
the realignment of the MYC oncogene with immunoglo-
bulin promoter/enhancer elements. Tumor lysis syndrome 
is an important complication that requires meticulous atten-
tion during the early phases of treatment. All of these traits 
al so  a pp l y  t o  A L L ,  L 3 an d  t h e  two entities are now considered 
to represent different aspects of the same disease.
In the early 1980’s, it became known that short, intensive 
treatment of childhood Burkitt lymphoma, rather than a 
protracted treatment course, as is commonly administered 
to patients with precursor B ALL, is highly effective [3]. 
Under this tenet, multi-center studies including the LMB 
and BFM studies have contributed significantly to improve 
the outcome of children with Burkitt lymphoma. Relying 
on agents such as cyclophosphamide, methotrexate, and 
cytarabine, and central nervous system (CNS)-directed ther-
apy, these studies have been crucial in elevating the pre-
viously dismal survival of the patients to 80% to 90% range. 
Initial successes in the pediatric population have also had 
a positive influence on the treatment of adults with Burkitt 
lymphoma, resulting in major advances in outcome for these 
patients as well.
In this issue of the Korean Journal of Hematology, Park 
et al. report the outcomes of children with Burkitt lympho-
ma/leukemia treated within a single institution in Korea 
in a long period spanning from 1991 to 2007 [4]. Major 
conclusions from their study include observations on im-
proved survival of patients treated with the LMB96 protocol 
in a later cohort of patients when compared to that of 
a historical cohort who were given D-COMP or CCG-106B 
protocol treatment. They also underscore that, despite im-
provements in outcome, CNS disease, high lactate de-
hydrogenase (LDH) levels at diagnosis, and poor initial treat-
ment response remain adverse prognostic factors.
Overall, their results mirror the progress that has been 
made in the treatment of Burkitt lymphoma throughout 
the decades, and, although from a single institution, may 
encapsulate and exemplify the treatment experience of 
Burkitt lymphoma. Intensive treatment of short duration 
indeed resulted in better outcomes for this disease. As in 
the LMB89 study, elevated LDH, poor response to initial 
treatment, such as the prephase of COP (cyclophosphamide, 
vincristine, prednisone), and CNS involvement were adverse 
prognostic factors [5]. However, the study by Park et al. 
parallels other major studies on Burkitt lymphoma in that 
the current shortcomings in diagnosis and treatment of this 
disease also become evident. The paper, while reflecting 
the successes of the past, emphasizes the unanswered ques-
tions of the disease that remain the tasks of the future.
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for the minority of patients who either relapse or are un-
responsive to primary treatment, valid options are limited 
and the prognosis is poor. For pediatric hematologists and 
oncologists living today, it is these children who warrant 
our attention and who may be better served by both better 
diagnosis and treatment.
With regards to diagnosis, cytogenetic studies are funda-
mental. It is interesting to note that even in the past LMB89 
study, cytogenetic data was only available in 175 out of 
561 patients eligible for analysis. However, such data, which 
have now become a basic component of initial diagnosis, 
are important not only for diagnostic verification, but also 
possibly as a mean of risk stratification. With the subsequent 
FAB/LMB 96 study reporting on the inferior outcomes of 
patients with +7q or del(13q) [6], results of cytogenetic 
studies may aid in predicting overall prognosis of the patient, 
and in dictating therapy.
The 2008 WHO classification lists a disease entity known 
as B-cell lymphoma, unclassifiable, with features inter-
mediate between diffuse large B cell lymphoma (DLBCL) 
and Burkitt lymphoma, evidence of the often indistinguish-
able barrier between these two disease states [7]. Future 
diagnostics should attempt to clarify diseases boundaries 
as much as possible, and studies on global gene expression 
profiling may aid in the accurate diagnosis of patients when 
morphological and immunohistochemical data give conflict-
ing or inconclusive results. Inaccurate initial diagnosis and 
therapy may result in subsequent resistance to treatment 
in this rapidly cycling tumor, with life-threatening conse-
quences.
Innovative therapeutic trials are also necessary. Use of 
monoclonal antibodies such as rituximab (anti-CD20 anti-
body) and epratuzumab (anti-CD22 antibody) for the treat-
ment of mature lymphoma has shown promising results 
in adult patient-based trials, and requires verification in 
children. A greater understanding of the role of MYC protein 
in both tumorigenesis and apoptosis may open a window 
into the use of novel therapeutic drugs [8].
So the next steps in the diagnosis and treatment of Burkitt 
lymphoma are daunting but necessary tasks: greater diag-
nostic clarity and possible risk stratification through both 
cytogenetic and molecular methods, and the implemen-
tation of new therapeutics in those who fail to respond 
to current strategies. Recent studies on patients with Burkitt 
lymphoma, as found in this issue, both validate the successes 
of the past and, above all, remind us of our current limita-
tions.
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